COVID Advisor

Viraldine™ from a New York based company (Viraldine LLC) is USP Povidone Iodine nasal spray with no damaging surfactants or fragrances. Available in 0.5%, 1% and 1.5% iodine nasal sprays and 1.5% throat spray.  Viraldine™ povidone iodine nasal spray is made exclusively by their partnering Compounding Pharmacists using only USP (US Pharmacopeia) ingredients which ensures the highest quality and trusted formulas available. When saturating your sinuses and throat with antiseptic povidone iodine nasal spray and throat spray, you could create an invisible shield protecting you and your family. Research shows PVP-I 1% Iodine Nasal Spray and 0.5% Povidone iodine nasal spray could also kill 99.9% of any germs or bacterial cells within your passages that have entered between regular applications and could prevent a more severe case. Research shows when germs & bacteria are treated at early onset, you could lower your risk of severe illnesses. Note: USP is the abbreviation for the US Pharma

The claim: Melatonin, aspirin, vitamins, zinc and quercetin can prevent or treat COVID-19? Since the early stages of the pandemic, people have claimed supplements like quercetin, zinc, vitamin D and melatonin can help treat and prevent COVID-19. But public health organizations and experts say there is little evidence these products are effective at treating or preventing COVID-19? Most of the studies on supplements are small and are of low quality? We shall wait for bigger and better quality evidence before we can make formal recommendations? Science requires questioning and testing. Trusting science without questioning is not science. The world does not exist in a 'black or white' manner and most of the time, things do fall into the 'gray' area. Medical science is dynamic and evidence development is constantly in a continuous work-in-progress mode. If a supplement has been shown to work in a small study, would you wait for a bigger study or should you just take it afte

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a preclinical study from researchers in the  Abramson Cancer Center at the University of Pennsylvania  and published  online in Cell Press’s iScience . Researchers show how two receptors—known as ACE2 and TMPRSS2—are regulated by the androgen hormone and used by SARS-CoV-2 to gain entry into host cells.  Transmembrane serine protease 2 (TMPRSS2) is a cell surface protein primarily expressed by endothelial cells across the respiratory and digestive tracts. Figure 1 Blocking the receptors with the clinically proven inhibitors and other anti-androgen therapies prevented viral entry and replication as showed in lab studies. The findings provide more insight into the molecular mechanisms of the virus but also support the use of anti-androgen therapies to treat COVID-19 infections, which are currently being investigated in

The Claim In an open letter to Trump dated March 23, 2020, and published online in various locations , Zelenko provided his first batch of assertions to support his treatment regime: I developed the following treatment protocol in the pre-hospital setting and have seen only positive results. […] The rationale for my treatment plan is as follows. […] We know that hydroxychloroquine helps Zinc enter the cell. We know that Zinc slows viral replication within the cell. Regarding the use of azithromycin, I postulate it prevents secondary bacterial infections. These three drugs are well known and usually well tolerated, hence the risk to the patient is low. Since last Thursday, my team has treated approximately 350 patients in Kiryas Joel and another 150 patients in other areas of New York with the above regimen. Of this group and the information provided to me by affiliated medical teams, we have had ZERO deaths, ZERO hospitalizations, and ZERO intubations. In addition, I have not heard of

Desert Review – Due to the aggressive aspect of the Delta variant of COVID-19, Imperial Valley frontline doctors, George Fareed and Brian Tyson, have submitted the following treatment recommendations below which are are more intensive. Dr. Brian Tyson and Dr. George Fareed participate in a Liberty Forum of Silicon Valley speaking from experience of treating thousands of COVID-19 patients successfully. For COVID patients with respiratory symptoms-in addition to the standard protocol with Hydroxychloroquine, Ivermectin, Doxycycline or Azithromycin, Zinc and vitamin D: 1. Obtain a chest Xray 2. Dexamethasone 6mg by injection IM ( intramuscular) or 8 mg orally 3. Budesonide 0.5mg/3ml four times daily via nebulization 4. Montelukast (Singulair) 10mg orally daily 5. Cyproheptadine 8mg orally four times a day 6. Colchicine 0.6mg orally daily 7. Fenofibrate 50mg orally three times a day 8. Aspirin 325mg orally daily Fareed/Tyson COVID-19 treatment protocols: Day 1 —

SUZHOU, China, Dec. 27, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection (NCT04870606). Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-to-moderate COVID-19 symptoms were enrolled. Kintor Pharma will seek for Health Authorities including the U.S. Food & Drug Administration's consent to amend the protocol and continue to enroll higher risk COVID-19 patients only with multiple comorbidities and/or patients with no COVID-19 vaccination history. Based on the interim analysis, there were no safety concerns and no drug-rela

ASSOCIATED PRESS  —  U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus. The long-awaited milestone comes as U.S. cases, hospitalizations and deaths are all rising and health officials warn of a tsunami of new infections from the omicron variant that could overwhelm hospitals. Paxlovid is no. 1 in this drug league table The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited. All of the previously authorised drugs against the disease require an IV (intravenous) or an injection. An antiviral  pill from Merck  also is expected to soon win authorization. But Pfizer’s drug is all but certain to be the preferred option because of its mild side effects and superior effectiveness, including a nearly 90% reduction in hospitalizations and deaths among patients most likely to get severe disease